Pay in 4 interest-free payments of $5.49 Learn more
Ships within 48 hours · Estimated delivery Aug 12 - Aug 17
The Phase 3 TRIUMPH-4 trial (NCT05869903) enrolled adults with obesity and knee osteoarthritis
The findings remained consistent at 12 months and 36 months, and the benefit was observed regardless of body mass index, weight loss or diabetes status
Volume purchased by the provider can influence pricing
However, compounded medications are not required to undergo the same rigorous testing for bioequivalence that generic drugs require
That third target appears to drive its larger trial weight loss
Rahman V (2025)
US$ 20.22
US$ 26.29
US$ 27.97
US$ 29.31
